Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Naringenin-functionalized polyester nanoparticles improve oral urolithin A delivery and protect against cisplatin-induced kidney injury via heme oxygenase-1 activation and mitochondrial quality control.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Dual-Ligand Targeted Nanoparticles Enhance In Vitro Delivery and Efficacy of Investigational Drug Candidate GAT211.

ACS applied bio materials·2025
Same author

Design and In Vitro Evaluation of Gambogic Acid-Conjugated Stearic Acid Solid Lipid Nanoparticles for Transferrin Receptor-Mediated Drug Delivery.

Pharmaceutical research·2025
Same author

Establishing PDE4 as a Novel Target of Urolithin-A in Mitigating LPS-induced Inflammation in Retinal Pigmented Epithelium Cells.

Pharmaceutical research·2025
Same author

UPLC-MS/MS Method for Simultaneous Quantification of Cyclosporine A and Urolithin A in Plasma and Interspecies Analysis Across Mammals Including Humans.

ACS omega·2025
Same author

Interplay between Skeletal Muscle Catabolism and Remodeling of Arteriovenous Fistula by Yes-Associated Protein 1 (YAP1) Signaling.

Journal of the American Society of Nephrology : JASN·2025
Same journal

Spatiotemporal control of myoblast identity drives muscle diversity in the <i>Drosophila</i> leg.

Science advances·2026
Same journal

Stellar feedback drives the baryon deficiency in low-mass galaxies.

Science advances·2026
Same journal

Antiferroelectric thin films embedded with ferroelectric switching loop for giant negative electrocaloric effect.

Science advances·2026
Same journal

Tetraphosphorylated phthalocyanine-based self-assembled monolayer stabilizes perovskite photovoltaics.

Science advances·2026
Same journal

Dual-mode analysis of ischemic stroke based on urine SERS spectra and carotid B-ultrasound.

Science advances·2026
Same journal

Remote homology and functional genetics unmask deeply preserved Scm3/HJURP orthologs in metazoans.

Science advances·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.5K

Dual-function polyester nanoparticles for amplified anti-inflammatory effects.

Ingrid M Heyns1,2,3, Abiodun T Wahab1,2,3, Raghu Ganugula1,2,3,4

  • 1Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, AL 35401, USA.

Science Advances
|August 6, 2025
PubMed
Summary
This summary is machine-generated.

This study developed dual-acting nanoparticles for enhanced intestinal drug delivery. These systems effectively combat inflammation and reduce the required dose for treating acute kidney injury (AKI).

More Related Videos

Procedure for Fabricating Biofunctional Nanofibers
09:39

Procedure for Fabricating Biofunctional Nanofibers

Published on: September 10, 2012

12.7K
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K

Related Experiment Videos

Last Updated: May 1, 2026

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique
06:47

Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique

Published on: September 20, 2011

37.5K
Procedure for Fabricating Biofunctional Nanofibers
09:39

Procedure for Fabricating Biofunctional Nanofibers

Published on: September 10, 2012

12.7K
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K

Area of Science:

  • Nanomedicine
  • Pharmacology
  • Immunology

Background:

  • Acute kidney injury (AKI) involves inflammation and fibrosis.
  • Naringenin (NAR) possesses anti-inflammatory properties but faces bioavailability challenges.
  • Targeted drug delivery systems can improve therapeutic efficacy and reduce side effects.

Purpose of the Study:

  • To develop and evaluate dual-acting nanoparticles for enhanced intestinal uptake and targeted delivery of naringenin (NAR).
  • To investigate the efficacy of these nanoparticles in combating inflammation and treating cisplatin-induced AKI.
  • To assess the role of nanoparticle formulation on immune modulation and therapeutic outcomes.

Main Methods:

  • Formulation of NAR-loaded passive nanoparticles [P2Ns(NAR)] and dual-acting systems [P2Ns-NAR(NAR)] utilizing NAR as a folate receptor ligand.
  • In vitro testing on cisplatin-induced human kidney-2 cells.
  • In vivo evaluation in a mouse model of cisplatin-induced AKI, assessing immune responses, kidney function, fibrosis, and molecular markers.

Main Results:

  • Both P2Ns(NAR) and P2Ns-NAR(NAR) demonstrated significant advantages over unformulated NAR, reducing effective dose by up to 57% and 79%, respectively.
  • Nanoparticles modulated immune responses, restored T cell function, and shifted macrophages to an M2 phenotype.
  • P2Ns-NAR(NAR) significantly alleviated AKI, reduced kidney fibrosis, and lowered levels of Toll-like receptor 4 and nuclear factor κB, showing a 50% lower effective dose compared to other formulations.

Conclusions:

  • Dual-acting nanoparticles effectively enhance intestinal uptake and therapeutic delivery of naringenin.
  • Naringenin-based nanoparticles show significant potential in treating inflammatory diseases like AKI by modulating immune responses and reducing tissue damage.
  • Polymer functionality is crucial for developing effective drug delivery systems that overcome biological barriers and improve treatment outcomes.